Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Cyclofenil”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed1981

Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients.

Cyclofenil was evaluated versus placebo in the treatment of progressive systemic sclerosis (PSS, scleroderma) in a 2 x 6-month double-blind crossover study. The mean duration of disease was six years. Of 38 patients entering the study, 27 completed both periods. Reasons for drop-outs were very high liver transaminases in three cases, cardiac death in two, and drug allergy, alcoholic problems, suspected congestive heart failure, reactivation of tuberculosis, arteriosclerotic heart disease, and lethal progression of PSS in one case each. No fatality was attributed to cyclofenil. Liver enzyme abnormalities were seen in 13 of 35 active drug periods and in 5 of 30 placebo periods. Cutaneous and visceral involvement were assessed by a large battery of subjective parameters and objective tests. Overall improvement was seen during 17 drug periods and nine placebo periods (N.S.), but a paired comparison of the status at the end of each treatment period resulted in the following distribution: 15 were improved at the end of the drug period, four at the end of placebo period (p less than 0.01) and eight were unchanged. In patients with a disease duration of five years or less, joint stiffness and pain were less on drug than on placebo treatment (p less than 0.05). In the whole group, oesophageal peristalsis improved (p less than 0.05). Blood folate increased (p less than 0.01). Working capacity was lower after the drug period than after the placebo period (p less than 0.05). Several other parameters, however, did not change significantly. Cyclofenil appears to be a promising drug in the treatment of PSS and should be tested further in controlled long-term studies.

Clinical Trials as Topic↗
PubMed2002

Mass spectrometric analysis of cyclofenil and its metabolites in human urine.

Using gas chromatography/electron impact-mass spectrometry (GC/EI-MS) and high performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry (HPLC/APCI-MS/MS), the structures of cyclofenil metabolites in human urine have been assigned. The hydroxyl metabolites liberated from the glucuronide conjugates after acid hydrolysis were characterized as the trimethylsilyl (O-TMS) derivatives using GC/MS. The conjugate glucuronide forms were detected without hydrolysis by HPLC/MS. Cyclofenil was not observed in urine. Tentative structures for the two metabolites are proposed.

Adult↗
PubMed1992

Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Results from a two-year randomized study.

In a two-year prospective therapeutic trial 13 patients with systemic sclerosis (SSc) were treated with penicillamine, 9 with cyclofenil, and 7 with neither. At entry skin involvement and esophageal, lung, heart, and kidney function did not differ significantly between the groups. Reevaluation after one and two years did not show any significant changes in skin, esophageal, heart, and kidney manifestations, while lung function had slightly improved in both drug-treatment groups. This study thus shows little overall effect of penicillamine and cyclofenil, although both drugs may arrest worsening of pulmonary dysfunction.

Adult↗
PubMed1990

[Sterility from hormonal causes and unexplained sterility. Treatment with cyclofenil. Double-blind controlled study].

We treated 213 women during 3 cycles by cyclofenil versus placebo in a double-blind study. These women had infertility caused by ovulatory deficiencies, a cervical factor or idiopathic infertility. Twenty-six of the 114 women receiving cyclofenil became pregnant and 21 of the 99 receiving the placebo. The cumulative pregnancy rates were identical in the 2 groups: 22 per cent in 3 cycles. The authors insist on the importance of a good doctor-patient relationship and the role of the placebo effect in any treatment of infertility.

Adult↗
PubMed1985

[Acute hepatitis caused by cyclofenil (Ondogyne). Apropos of 2 cases].

We report the cases of two adults suffering from acute hepatitis due to cyclofenil (Ondogyne), a drug proposed for the treatment of dysovulation and scleroderma. Hepatitis developed 30 and 102 days after the beginning of discontinuous administration of the drug. A challenge test was positive in both cases. The course of hepatitis was reversible after withdrawal of the drug. Hepatitis induced by cyclofenil is likely to be due to an hypersensitivity mechanism.

Acute Disease↗
PubMed1980

Serum prolactin levels during inhibition of lactation by cyclofenil.

Inhibition of lactation is now usually achieved by the use of dopaminergic or antiserotoninergic drugs. An interesting, alternative approach, however, is represented by the use of antiestrogenic agents, though their mechanism of action is still uncertain. We have given cyclofenil at daily doses of 1200, 800 and 600 mg to a total of 100 post-partum women who required not to lactate. The clinical results were excellent or good in 83 women, fair in 9 and poor in 8. After 3, 5, and 7 days of treatment serum prolactin levels of treated women, if compared with those of control group, showed a decrease ranging from 25 to 27%, from 42 to 44%, and from 60 to 64% respectively. Blood coagulation, as judged by several laboratory parameters, did not show abnormal changes in any subject treated with cyclofenil.

Cresols↗
PubMed1977

The use of cyclofenil in menopausal women.

On the basis of some reports, a double-blind experimental trial comparing the activity of cyclofenil, estradiol valerate and placebo in post-menopausal disturbances was carried out. 60 women among those attending the menopausal clinic and affected by climateric disorders have been treated. The objective criterium for the admission had been established on the basis of the value of plasma FSH (greater or equal to 800 ng/ml). Besides the gynecological examination (including objective and subjective examination, hormone dosage, endometrial biopsy) patients underwent psychological examination (individual interview and psychometric tests) before and after 28 days of therapy The statistical evaluation of the results obtained with the 3 drugs showed a statistically significant difference between the placebo and the active compounds: no significant difference between cyclofenil and estradiol valerate was observed.

Cresols↗
PubMed1981

Plasma levels and pharmacokinetics of cyclofenil after oral administration to man.

Cyclofenil was given as a single oral dose of 200 mg, and also as 200 mg/day for eight days, to seven healthy female volunteers. Plasma was analyzed for the active metabolite and pharmacokinetic modelling was performed. A biological half life of 29 h was bound after the single dose and 18 h after the eighth day of continuous treatment. No significant difference was found in any of the calculated parameters when comparing the values from Day 1 and Day 8. The theoretically constructed steady-state curve fitted the experimented values.

Administration, Oral↗
PubMed1980

HDL-increasing effect of cyclofenil.

Nineteen patients with low levels of HDL as measured by APO-AI have been treated with cyclofenil (a non-steroid stilboestrol isomer with very low oestrogenic effects) as the only form of therapy. The therapy elicited a highly significant rise of about 15% in HDL levels. A slight increase in transaminases occurred in 6 patients but was reversible without terminating therapy.

Cholesterol↗
PubMed1980

Effect of cyclofenil treatment on arterial insufficiency demonstrated in a patient by colour thermography.

Cyclofenil, 200 mg t.i.d., was administered for four months to a 67-year-old woman, who suffered from a combination of scleroderma, Osler-Weber-Rendu disease and a severe atherosclerotic circulatory insufficiency. The effects on the severely impaired skin circulation in the face and hands were followed and recorded by colour isothermograms, using the AGA monitor system. The treatment resulted in a marked improvement of the arterial circulation with disappearance of the Raynaud phenomenon, complete arrest of gastrointestinal bleeding, disappearance of malabsorption, and relief of the joint stiffness.

Aged↗
PubMed1981

Synthesis of collagen and sulfated glycosaminoglycans by normal and scleroderma fibroblasts in culture, with and without addition of cyclofenil.

The influence of the synthetic weak estrogen cyclofenil was studied in vitro on skin fibroblasts from scleroderma patients, normals, and human embryos. The drug had no effect on the synthesis of sulfated glycosaminoglycans or collagen. Collagen synthesis was lower in scleroderma fibroblasts than in normal cells, whereas there was no difference in sulfated glycosaminoglycans synthesis.

Adult↗
PubMed1983

Hepatic reactions to cyclofenil.

Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed. The liver damage was probably related to metabolic idiosyncrasy, and was reversible in all patients.

Adult↗
PubMed1998

Retrograde trafficking of both Golgi complex and TGN markers to the ER induced by nordihydroguaiaretic acid and cyclofenil diphenol.

Previous studies have shown that the Golgi stack and the trans-Golgi network (TGN) may play a role in capturing escaped resident endoplasmic reticulum (ER) proteins, and directing their retrograde transport back to that organelle. Whether this retrograde movement represents a highly specific or more generalized membrane trafficking pathway is unclear. To better understand both the retrograde and anterograde trafficking pathways of the secretory apparatus, we examined more closely the in vivo effects of two structurally unrelated compounds, the potent lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA), and the non-steroidal estrogen cyclofenil diphenol (CFD), both of which are known to inhibit secretion. In the presence of these compounds, transport of vesicular stomatitis virus G membrane glycoprotein from the ER to the Golgi complex, and from the TGN to the cell surface, was inhibited potently and rapidly. Surprisingly, we found that NDGA and CFD stimulated the rapid, but not concomitant, retrograde movement of both Golgi stack and TGN membrane proteins back to the ER until both organelles were morphologically absent from cells. Both NDGA- and CFD-stimulated TGN and Golgi retrograde membrane trafficking were inhibited by microtubule depolymerizing agents and energy poisons. Removal of NDGA and CFD resulted in the complete, but not concomitant, reformation of both Golgi stacks and their closely associated TGN compartments. These studies suggest that NDGA and CFD unmask a generalized bulk recycling pathway to the ER for both Golgi and TGN membranes and, further, that NDGA and CFD are useful for investigating the molecular mechanisms that control the formation and maintenance of both the Golgi stack proper and the TGN.

Adaptor Proteins, Vesicular Transport↗
PubMed1980

Improvement of lung function in a scleroderma patient treated for 12 months with cyclofenil.

A 48 year old male scleroderma patient with typical impairment of respiratory function, including low vital capacity, low static lung compliance and low diffusing capacity for carbon monoxide, was treated with cyclofenil for one year. Assessment of lung function after 3, 6 and 12 months treatment showed marked improvement of vital capacity, increased physical working capacity, less hypoxia at maximum work, increase of static lung compliance and decreases of maximal transpulmonary pressure. Closing capacity decreased, and an increase in difussing capacity for carbon monoxide was seen.

Cresols↗
PubMed1985

Evaluation by integrated thermography of the beneficial effect of cyclofenil in severe subcutaneous arterial insufficiency.

Integrated thermographic measurements were made in a patient suffering from a complex syndrome which included scleroderma, Osler-Weber-Rendu disease and a marked atherosclerotic circulatory insufficiency. A new anti-estrogenic drug, cyclofenil, elicited a rapid and prolonged curative effect against the entire syndrome. The circulatory amelioration was registered periodically by integrated thermography of the face and both hands. This method enables temperature distribution functions to be calculated and seems to hold considerable promise for the evaluation of circulatory changes and in particular those changes evoked by therapeutic agents.

Aged↗
PubMed1992

Acute hepatitis induced by cyclofenil: a case report.

The case of a 47-year old woman suffering from acute hepatitis caused by cyclofenil, a drug proposed for the treatment of anovulation and scleroderma, is presented. Hepatitis developed seven weeks after the beginning of administration of the drug and its course was reversible after withdrawal. The case is documented on the basis of liver histology and the exclusion of other causes of acute hepatitis.

Acute Disease↗
PubMed1977

[Ovulation induction by cyclofenil (author's transl)].

The ovulation-inducing action of cyclofenil was investigated in 135 sexually mature women aged 20--35 years. The patients were only included in the trial if no ovulation in 2 consecutive cycles with the following criteria: basal temperature, cervix score, ascorbic acid retention, basophil count, serum hormone levels, e. g. LH and progesterone and the estrogens in the 24-hour urine could be determined. Ovulation was only considered to have occurred when all the parameters named indicated it. The lack of ovulation was accompanied by amenorrhea in 21 of the 135 patients. The ovulation rate in the 241 cycles observed was 101, corresponding to 42%. In the 114 patients with anovulatory cycles, the ovulation rate in the 184 cycles observed was 95, corresponding to 50%. In the 21 amenorrheic patients, ovulation occurred 6 times in the 57 cycles observed. Nausea or vomiting occurred as side effects in only 2 cases.

Adult↗